# Enlaza Therapeutics

Source: https://onco.cc/companies/enlaza-therapeutics/  
OnCo record `enlaza-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Enlaza Therapeutics engineers protein drugs that lock permanently onto their target once they find it, which could let antibody-based cancer medicines work at lower doses with fewer side effects. Its programmes are still in laboratory development.

## Summary

Enlaza Therapeutics (La Jolla, California) is building the first covalent biologic platform. Its War-Lock technology introduces proprietary unnatural amino acids into protein therapeutics so that they bind irreversibly to disease-relevant targets while remaining latent until target engagement, with the aim of improving efficacy and reducing toxicity for antibody-drug conjugates, T-cell engagers and other protein drugs, initially in oncology. The pipeline is preclinical and undisclosed. The company launched in December 2022 with USD 61 million in seed financing led by Avalon Ventures and raised a USD 100 million Series A in April 2024 led by the Life Sciences group of J.P. Morgan Private Capital, with Amgen Ventures and Regeneron Ventures among new investors. In September 2025 it announced a strategic collaboration with Vertex Pharmaceuticals to develop War-Lock drug conjugates and T-cell engagers for conditioning and certain autoimmune diseases.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: La Jolla, CA
- Type: biotech
- Website: https://enlazatx.com/

## Notes

- The website blocks scripted curl requests (Cloudflare) but was fetched via WebFetch; press release pages fetched directly. The Vertex collaboration is outside oncology.

## Sources

- Official website: https://enlazatx.com/
- Seed financing release: https://enlazatx.com/press_release/enlaza-therapeutics-launches-with-61-million-financing-to-advance-the-first-covalent-biologic-therapeutic-platform/
- Series A press release: https://enlazatx.com/press_release/enlaza-therapeutics-raises-100-million-through-its-series-a-financing-led-by-the-life-sciences-group-of-j-p-morgan-private-capital/

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Site-specific conjugation & linker chemistry](https://onco.cc/technologies/site-specific-conjugation/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- companies: [Alexandria Venture Investments](https://onco.cc/companies/alexandria-venture-investments/), [Amgen Ventures](https://onco.cc/companies/amgen-ventures/), [Frazier Life Sciences](https://onco.cc/companies/frazier-life-sciences/), [Lightspeed Venture Partners](https://onco.cc/companies/lightspeed-venture-partners/), [Samsara BioCapital](https://onco.cc/companies/samsara-biocapital/)

---
JSON: https://onco.cc/api/v1/entities/enlaza-therapeutics.json